|
|||||
|
|
Phase II trial of echinomycin for the treatment of advanced renal cell carcinoma |
|
| Authors: | M Ernest Marshall Michael K Wolf E David Crawford Sarah Taylor Brent Blumenstein Robert Flanigan Fredrick J Meyers Harry E Hynes Bart Barlogie Mario Eisenberger |
| Institution: | (1) University of Cincinnati, Cincinnati, OH;(2) Southwest Oncology Group Statistical Center, Seattle, WA;(3) University of Colorado, Denver, CO;(4) University of Kansas Medical Center, Kansas City, MS;(5) Loyola University Stritch School of Medicine, Maywood, IL;(6) University of California-Davis, Sacramento, CA;(7) Wichita CCOP, Wichita, KS;(8) University of Arkansas for Medical Science, Little Rock, AR;(9) University of Maryland, Baltimore, MD, USA |
| Abstract: | Summary Forty-nine patients with metastatic or recurrent renal cell carcinoma were treated on a phase II trial of Echinomycin. Treatment consisted of Echinomycin 1.25 mg/m2 intravenously every 28 days. Among the 47 evaluable patients there were no complete responses and only one partial response for an overall response rate of 2% (95% confidence interval, 0–11%). Eighteen patients (38%) experienced toxicity of grade 3 or worse. The most common toxicities were nausea and vomiting. The results of this study indicate that Echinomycin is not sufficiently active to warrant further trials for the treatment of renal cell carcinoma. |
| Keywords: | echinomycin renal cell carcinoma kidney |
| 本文献已被 SpringerLink 等数据库收录！ | |